Original Publication Date: 7 February, 2014
Publication / Source: Clinical Practice
Authors: Monica S Thakar, Julie-An M Talano, Richard L Tower, Michael E Kelly & Michael J Burke
Allogeneic hematopoietic cell transplantation (HCT) for pediatric acute leukemia continues to offer a cure for some patients with high-risk or relapsed disease. Presently, HCT in first remission is recommended only for patients with predicted leukemia-free survival <50%. Despite recent advances, relapse remains the biggest hurdle in HCT.